Rexis Biotech’s Post

Exciting insights from our recent roundtables, hosted in partnership with @AusBiotech. We were joined by more than 90 Biotech CEOs to discuss funding challenges, navigating regulatory changes, and talent acquisition. Read more about our discussions and how we can support your journey: https://lnkd.in/gwNc4P48

Navigating the funding landscape can be tricky for biotech companies at all stages, from initial research and clinical trials to scaling up capabilities. Our recent roundtable discussions with over 90 Biotech CEOs, held in partnership with AusBiotech, shed light on the challenges and opportunities shaping the industry. Discover how to navigate the complexities of funding and innovation in the biotech sector in our latest article: https://okt.to/ugJm1o #Biotech #LifeSciences

High attendance at our panel discussion with representatives of the investor, industry and payer communities highlighting the importance of considering payers‘ perspectives as early as at preclinical stage #marketaccess #payers #biotech #syneoshealth #innovation #swissbiotechday

Roel Bulthuis, Managing Partner and Head of Investments at Syncona, was featured in the latest edition of ‘Scrip Asks...’ Discussing the industry’s funding environment, M&A and partnering, Roel commented that although capital access constraints are likely to continue well into the new year, there are signs for optimism. Value recognition is shifting further towards later-stage clinical stage assets, and we expect the ‘feeder dynamic’ between #biotech and #pharma to grow, where we’ll see pharma continue to replenish its portfolio with the late-stage innovation coming out of biotechs. Read the full article here: https://lnkd.in/eCKp9ZMA #lifesciences #funding #partnerships

We were proud to be selected as one of the Fierce Biotech Fierce 15 2024 Honorees. We asked ourselves – what makes us fierce? Here is what our team said #5. We are responsible: We take personal and collective responsibility for delivering our shared goals. We hold ourselves and each other accountable – to our patients, colleagues, investors, as well as our work and mission. We apply the necessary rigor to ensure high quality. We are self-motivated and rely on each other to operate and perform at the highest levels. Read more about how OMassians are transforming lives together, our values and our team HERE: https://lnkd.in/ddaju6xf #innovation #biotech #drugdiscovery

We were proud to be selected as one of the Fierce Biotech Fierce 15 2024 Honorees. We asked ourselves – what makes us fierce? Here is what our team said #3. We are ambitious: We are driven by our shared mission to discover, develop and deliver impactful medicines to patients using cutting edge science. We are motivated to push boundaries and think big as we tackle challenges we confront as a company. We take a proactive approach towards research, and we are intentional in setting our short-term and long-term goals. Read more about how OMassians are transforming lives together, our values and our team HERE: https://lnkd.in/ddaju6xf #innovation #biotech #drugdiscovery

Developing a revolutionary biotech product is just the first step. But do you have the commercialization strategy to take it to the next level? Join our exclusive Better Biotech Growth webinar series, where we explore the key steps for turning biotech innovations into market success. Don’t miss the first session — Register today and get ahead of the curve: skp.link/iv25 #BetterBiotechGrowth #Biotech #CommercialExcellence #SimonKucher #BiotechGrowth

Developing a revolutionary biotech product is just the first step. But do you have the commercialization strategy to take it to the next level? Join our exclusive Better Biotech Growth webinar series, where we explore the key steps for turning biotech innovations into market success. Don’t miss the first session — Register today and get ahead of the curve: skp.link/iv25 #BetterBiotechGrowth #Biotech #CommercialExcellence #SimonKucher #BiotechGrowth

Despite recent challenges, venture capitalists are once again showing support for innovation, with investments reaching $3.2 billion compared to the $3 million we saw in the same period last year. What's driving this surge? 🚀 Improved stock market performance 💵 M&A activity instilling confidence  📈 Initial public offerings (IPOs) Keep your eyes peeled for May’s edition of i-Pharm Insights coming next week where we take a deeper dive into these investments and how they are impacting biotech. #biotech #iPharm

🚀 Exciting News in #Biotech Funding! 🚀 Profluent , a #California-based #AI-driven protein design company, secures an additional $35 million in financing, with backing from Spark Capital and other investors. This latest funding round brings #Profluent's total raised capital to $44 million, fueling its mission to leverage AI in decoding life's language and revolutionize #protein engineering. With this investment, Profluent aims to pioneer innovative solutions and validate groundbreaking approaches in the field. Connect, Repost & Follow for more insights on biotech advancements! 🧬 #biotech #AI #proteinengineering #innovation #funding #fda #ema #pharma #pharmaceuticalindustry #pharmaindustry